Coverage
-
January 30, 2013
A Delaware federal judge on Wednesday rejected Watson Pharmaceuticals Inc.'s claims that Pfizer Inc.'s patent for the organ rejection drug Rapamune was invalid, handing Pfizer a victory in its efforts to halt abbreviated new drug applications for generic versions of the drug.
1 other articles on this case.
View all »